bold = Main text
     Part,  Chapter, Paragraphgrey = Comment text

5001 III, 10. 2. 1 | substances, such as LSD, GHB, Ketamine and a wide range of other - 5002 II, 5. 5. 3 | Battaglia M, Kesselring J, Ketelaer P, Thompson A et al; (2004): 5003 II, 9. 2. 7 | publications/2006/hiv_sti_2006/pdf/keypoints_recommend.pdf (accessed 5004 Key | LIST OF KEYWORDS~ ~ 5005 III, 10. 2. 1 | to nicotine, there is a “kickcaused in part by the drug’ 5006 II, 5. 7. 6 | niddk.nih.gov/Divisions/kuh/kidneyHP2010.htm).~ ~In most Member States, 5007 II, 5. 5. 3 | expected at puberty; inoculate kids against media manipulation ( 5008 II, 5. 5. 3 | Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, 5009 II, 9. 1. 2 | De Vigan C, Fevotte J, Kiel G, Mandereau L, for the 5010 II, 9. 3. 1 | Hobbs, F.D.R. Fourcade R. Kiemeney , L, Lee C. and the UrEpik 5011 II, 5. 5. 3 | Morosini P, Polidori G, Kikkawa T, Kawakami N, Ono Y, Takeshima 5012 II, 5. 5. 3 | 1185.~Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992): The accuracy 5013 II, 5. 2. 1 | and stroke, are the main killers in both genders and all 5014 II, 5. 4. 4 | calculated by weight in kilogram divided by the square of 5015 II, 5. 2. 6 | Fidanza F, Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu 5016 IV, 12. 10 | children):~“easy-peasy” (“Kinderleicht”, see www. – supported by 5017 -, 1 | of many experts who have kindly accepted to collaborate 5018 II, 9. 5. 3 | of the family~United Kingdomb, f~· 25% women had been 5019 III, 10. 2. 1 | Reviews 7:233-237.~ ~Dolman R, Kingdon A, Roberts C, eds (2007): 5020 III, 10. 4. 2 | Sata, F, Yoshimura, Y, Kishi, R, Nakazawa, H.(2004). 5021 II, 5. 5. 3 | M, Rummel C, Wahlbeck K, Kissling W (2006): Call for a European 5022 II, 9. 5. 3 | Morris, 2001; Armstrong and Kits, 2004). More women than 5023 II, 5. 5.Int(15)| R, Hooijer C, Lawlor BA, Kivela S-L, Lobo A, Magnusson H, 5024 III, 10. 2. 1 | fbdg_2007.pdf]~ ~Ekholm O, Kjøller M, Davidsen M, Hesse U, 5025 II, 5. 6. 6 | Ferraccioli G, Hazes JM, Klareskog L, Machold K, Martin-Mola 5026 II, 5. 7. 7 | donoghue DJ, de LS, Van VJ, Klebe B, Middleton R, et al (2007): 5027 III, 10. 2. 4 | Ibarreta D, Bock, A.K., Klein C, Rodriguez-Cerezo E (2003): 5028 II, 9. 1. 2 | M, Bower C, Milne E, de Klerk N, Kurinczuk JJ (2005): 5029 II, 5. 5. 3 | Soyka, L.A, Herzog, D.B, Klibanski, A. (2004): Effects of Anorexia 5030 II, 5. 5. 3 | changes in metabolism. Wien Klin Wochenschr 118 (7-8):196- 5031 II, 5. 5. 3 | 27(9):561-568.~Riedel O, Klotsche J, Spottke A, Deuschl G, 5032 II, 9. 3. 1 | Braun, M., Wassner, G Klotz, T Reifenrath, B Mathers, 5033 III, 10. 2. 1 | 1174-1179.~ ~Grabauskas V, Klumbienė J, Petkevičienė J, Šakytė 5034 II, 5. 5. 3 | Milanov I, Georgiev D, Kmetska K, Jordanova L, Topalov 5035 II, 5. 7. 7 | 16 Suppl 7:57-60~Lin J, Knight EL, Hogan ML, Singh AK ( 5036 II, 9. 1. 2 | Calzolari E, De Walle H, Knill-Jones R, Candela S, Dale I, Danaché 5037 II, 5. 2. 7 | 28: 2375-414~Greenland P, Knoll MD, Stamler J,. Neaton JD, 5038 III, 10. 1. 3 | Friesema IHM, Garretsen HFL, Knottnerus JA, Zwietering PJ (2006): 5039 II, 7. 5 | injury and violence requires knowledgeable and skilled staff. Medical 5040 II, 9. 2. 5 | treated by a physician who knows them all, is paramount. 5041 II, 5. 5. 3 | P, Pugliatti M, Lauer L, Kobelt G (2007): Estimation of 5042 II, 5. 10. 7 | Anklam E, Baumgartner S, Koch P, Crevel RW, Frewer L ( 5043 IV, 11. 6. 5 | Equity in Health.~ ~Gibis B, Koch-Wulkan PW et al. (2004): Shifting 5044 II, 4. 3 | References~ ~Anderson R, Kochanek K, et al. (1997): Report 5045 III, 10. 2. 4 | Kononen J, Haas P, Zuber M, Köchli OR, Mross F, Dieterich H, 5046 II, 5. 5. 1 | 118(4):330-41.~ ~Värnik A, Kölves K, van der Feltz-Cornelius 5047 III, 10. 2. 1 | Elmadfa I, Freisling H, König J et al. Austrian Nutrition 5048 III, 10. 2. 1 | Fragen zur Gesundheid – Körpermaße der Bevölkerung 2005 [Microcensus - 5049 II, 5. 6. 6 | 1709~Hakala M, Nieminen P, Koivisto O (1994): More evidence 5050 III, 10. 2. 1 | Central Books.~ ~Hassmen P, Koivula N, Uutela A (2000): Physical 5051 III, 10. 2. 1 | Unpublished document.~ ~Koivusilta L, Honkala S, Honkala E, 5052 II, 5. 5. 3 | Neurol 53:793-798.~Gross K, Kokk A, Kaasik AE (1993): Prevalence 5053 III, 10. 2. 1 | A, Miller AB, Boeing H, Kolyva M, Saieva C, Celentano E, 5054 II, 5. 5. 3 | Wrigley S, Jackson H, Judd F, Komiti A (2005): Role of stigma 5055 IV, 12. 10 | German Medical Association (Kommission Somatische Gentherapie der 5056 II, 5. 5. 3 | Dan Med Bull 48: 9194.~Koncan-Vracko B (1994): Epidemiological 5057 III, 10. 4. 1 | Intervention studies~- Dublin, Hong Kong, etc.~ ~· Cohort studies~- 5058 II, 5. 3. 7 | detectable (Hakama and De Konig, 2007).~ ~Screening has 5059 II, 5. 3. 9 | 3742-3751.~ ~Hakama M, De Koning H (2007): Portuguese Presidency 5060 III, 10. 5. 1 | Global Change Biology.~Konlaan, B B. Bygren, L O. Johansson, 5061 III, 10. 5. 1 | and better mental health (Konlan et al, 2000; Bohnert and 5062 II, 5. 6. 6 | WJ, Bonneux L, Polder JJ, Koopmanschap MA, van der Maas PJ (1998): 5063 III, 10. 5. 1 | studies from China and South Korea have demonstrated that schools 5064 II, 5. 5. 3 | Merikangas KR, Anthony JC, Von Korff MR, Wang PS, Brugha TS, 5065 III, 10. 6. 1 | study, performed in 2001 (Korkeila et al., 2003), measured 5066 II, 9. 3. 3 | CH, Johnson AM, Cpas AJ, Korovessis C, fenton KA, Fiels J (2001): 5067 II, 5. 8. 7 | Nissinen A, Tukiainen H, Koskela H (2006): Thirty-year cumulative 5068 II, 6. 3. 7 | been reported in Turkey, Kosovo and Albania. Eurosurveillance 5069 IV, 12. 10 | initiative is called “Alt om kost “ (Everything about diet) 5070 II, 5. 6. 6 | and Lindgren B (1996): Vad kostar sjukdomarna? (What are the 5071 II, 5. 5. 3 | Opin Neurol 17:141-146.~Kotsopoulos IAW, van Merode T, Kessels 5072 II, 5. 5. 1 | 168(Suppl. 30):1730.~ ~Kovess-Masféty V, Alonso J, Brugha TS, 5073 II, 5. 10. 7 | Hiller R, Hourihane JO, Kowalski M, Papadopoulos NG, Wal 5074 II, 5. 6. 6 | Sturmer T, Puhl W, Gunther KP, Brenner H (2003): International 5075 III, 10. 2. 1 | Health Nutr. 4: 537-545.~ ~Kraemer K, Zimmermann MB (ed.). 5076 II, 5. 5. 3 | Planning 16;326-331.~Freal JE, Kraft GH, Coryell JK (1984): Symptomatic 5077 II, 8. 2. 1 | G, Heller T, Holland A, Krahn G, Lennox N, Meaney J & 5078 II, 5. 11. 7 | 81:268272.~ ~Weismann K, Krakauer R, Wanscher B (1980): Prevalence 5079 II, 8. 2. 1 | Disabilities 18, 295-304.~Kramers, P.G.N., (2003). The ECHI 5080 II, 9. 3. 1 | Aytac, I., McKinlay, J. & Krane, R. (1999) The likely worldwide 5081 II, 5. 5. 3 | 2007): Prävalenzen seltener Krankheiten: eine Literaturstudie. Available 5082 III, 10. 1. 3 | Obes 22:354-362.~Babor TF, Kranzler HR, Lauerman RJ (1987): 5083 II, 5. 5. 3 | Epilepsia 43:445-450.~Sheth SG, Krauss G, Krumholz A. Li G (2004): 5084 III, 10. 3. 1 | Forastiere F, Hakama M, Heid I, Kreienbrock L, Kreuzer M, Lagarde F, 5085 II, 5. 8. 7 | Blanc P, Henneberger P, Kreiss K, Mapp C, Milton D, Schwartz 5086 III, 10. 3. 1 | Heid I, Kreienbrock L, Kreuzer M, Lagarde F, Mäkeläinen 5087 III, 10. 2. 1 | Petkevičienė J, Šakytė E, Kriaučionienė V, Paalanen L, Prättälä 5088 III, 10. 5. 3 | Siegrist, J. (1996). Soziale Krisen und Gesundheit. Göttingen: 5089 II, 5. 4. 8 | S215 – S219~Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen 5090 III, 10. 2. 1 | Visscher TLS, Viet LA, Kroesbergen HT, Seidell JC (2006): Underreporting 5091 III, 10. 4. 2 | kitchens~ ~Baars et al., 2001;~Kroese et al., 2001;~SCF, 2002~ ~ 5092 IV, 11. 6. 5 | 18(2): 79-80.~ ~Mainz J, Krog BR et al. (2004): "Nationwide 5093 III, 10. 2. 1 | K, San-Jose B, Welch AA, Krogh V, Luben R, Allen N, Overvad 5094 II, 5. 5. 3 | and GP contacts~245 ~2.3 ~Krohn, 1961 (*) ~Poland~All ages ~ 5095 III, 10. 2. 1 | MC, Naska A, Miller AB, Kroke A, Bamia C, Karalis D, Vineis 5096 III, 10. 1. 3 | 3):212-216.~Collins JJ, Kroutil LA, Roland EJ, Moore-Gurrera 5097 II, 5. 5. 3 | 231.~Poser S, Stickel B, Krtsch U, Burckhardt D, Nordman 5098 III, 10. 3. 1 | N 1313.~Kempen EEMM van, Kruize H, Boshuizen HC, Ameling 5099 II, 5. 5. 3 | 450.~Sheth SG, Krauss G, Krumholz A. Li G (2004): Mortality 5100 II, 5. 12. 7 | References~ ~Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan 5101 I, 2. 11 | europa.eu/cache/ITY_OFFPUB/KS-AF-05-001/EN/KS-AF-05-001-EN.PDF]~ ~ 5102 I, 2. 11 | ITY_OFFPUB/KS-AF-05-001/EN/KS-AF-05-001-EN.PDF]~ ~EUROSTAT (2008): 5103 III, 10. 6. 1 | Netherlands, 1985.~ ~Kohb M, Künemund H, Lüdicke J. (2005): Family 5104 II, 5. 7. 6 | niddk.nih.gov/Divisions/kuh/kidneyHP2010.htm).~ ~In 5105 II, 5. 5. 3 | Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach 5106 II, 5. 5. 3 | Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M ( 5107 II, 7. 4. 1 | group die due to injuries (Kumpala & Paavola 2008); this figure 5108 II, 7. 7 | für Verkehrssicherheit.~ ~Kumpula et al (2008): Injuries and 5109 II, 5. 3. 9 | G, Micheli A, Mangone L, Kunkler I, and the EUROCARE-4 Working 5110 III, 10. 2. 1 | Fagerström K, Jarvis MJ, Kunze M, McNeill A, Ramström L ( 5111 II, 5. 8. 7 | A, Sunyer J, Neukirch F, Kunzli N, Leynaert B, Janson C, 5112 II, 5. 9. 7 | Stunyer J, Janson C, Svanec C, Kunzly N, (2005): Change in prevalence 5113 III, 10. 2. 4 | S, Dudas ME, Leung DHY, Kuo D, Brennan MF, Lewis JJ, 5114 II, 5. 6. 6 | Worthington JW, O'Fallon WM, Kurland LT (1980): The epidemiology 5115 II, 5. 7. 7 | Chen J, Wildman RP, Gu D, Kusek JW, Spruill M, Reynolds 5116 II, 5. 7. 7 | Vittinghoff E, Kanaya AM, Kushel MB (2007): Food insecurity 5117 II, 5. 2. 7 | Asplund K, rastenyte D, Kuulasma K, Vanuzzo D, Tuomilehto 5118 III, 10. 2. 1 | Kasler M, Kogevinas M, Kvinnsland S, La Vecchia C, Levi F, 5119 III, 10. 3. 1 | 266-274.~Torfs R (2003). Kwantificering van gezondheidsrisico’s 5120 II, 9. 3. 3 | M, Wyness L, Bloemenkamp KWM, Jahn A, Karro H, Olsen 5121 III, 10. 4. 2 | Czech Republic~Υπουργείου Υγείας της Κυπριακής Δημοκρατίας~Cyprus~Fødevarinstituttet 5122 IV, 12. 4 | 1999, succeeded by Markos Kyprianou in 2004 and Androulla Vassiliou 5123 II, 5. 5. 3 | Almazan, C, Worley, M,. Soyka, L.A, Herzog, D.B, Klibanski, 5124 III, 10. 5. 1 | environment. In: Berkman, L.F., Kawachi, I. (eds.): Social 5125 II, 5. 8. 7 | goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989] (on-line 5126 II, 5. 8. 7 | com/Guidelineitem.asp?l1=2&l2=1&intId=989] (on-line publication, 5127 II, 5. 5.Int(21)| 06.2002, Official Journal L232/1 of 29.08.2002; Official 5128 II, 5. 5.Int(21)| 12.1998, Official Journal L26/1 of 01.02.1999,.Sixth Framework 5129 II, 5. 10. 2 | biological substance~ICD-10~L27.2~Dermatitis due to ingested 5130 II, 5. 5.Int(21)| 08.2002; Official Journal L294/1 of 29.10.02.~ 5131 II, 9. 2. 7 | eurosafe2006.nsf/wwwVwContent/l3childsafetyactionplanning.htm?OpenDocument~ ~European 5132 II, 5. 5. 3 | Larsen JP, Tandberg E, Laake K (2000): Predictors of 5133 II, 6. 3. 1 | from a ‘clinic-based’ to a ‘laboratory-basedsurveillance has important 5134 II, 6. 3. 2 | microbiologists, HCAI surveillance is labour-intensive and therefore targeted at 5135 III, 10. 3. 4 | injuries (sprains/strains, lacerations, "other injuries" as well 5136 II, 8. 2. 1 | Craig, E.M., Gomez, S.C., Lachapelle, Y., Reeve, A., Snell, M. 5137 II, 5. 7. 7 | BC, Briggs JP, Eggers PW, Lacher DA, et al (2005): Chronic 5138 II, 9. 1. 2 | Drugs during pregnancy and lactation: handbook of prescription 5139 II, 9. 3. 1 | decreased production of lactic acid and an environment 5140 II, 5. 10. 5 | other alcoholic beverages; lactitol.~ ~(e) nuts used for making 5141 II, 5. 10. 5 | products thereof (including lactose) (d)~- Nuts and products 5142 II, 5. 10. 7 | K, Herouet-Guicheney C, Ladics G, Bannon G, Cockburn A, 5143 II, 5. 4. 8 | gender perspective. Ugeskr Laeger. 18;169(25):2432-4 [Article 5144 IV, 12. 10 | Ordinance (BbodSchV) 1999. The Länder are responsible for the 5145 III, 10. 3. 1 | Directive 2002/49/EC on~LAeq~A-weighted average sound 5146 III, 10. 3. 1 | average sound pressure level.~LaeqT~Exposure to noise for the 5147 III, 10. 2. 1 | H, Holm AK, Kallestal C, Lagerlof F, Lingstrom P, Mejare I, 5148 III, 10. 6. 2 | E, Costa G, Geurts JJM, Lahelma E, Van Oyen H, Rasmussen 5149 II, 5. 11. 3 | RJ, Jolanki R, Kalimo K, Lahti A, Lammintausta K, Lauerma 5150 II, 9. 2. 7 | Ståhl T, Wismar M, Ollila E, Lahtinen E, Leppo K (eds.) (2006): 5151 II, 5. 5. 3 | 2590.~Engl J, Tschoner A, Laimer M, Rettenbacher M, Fleischhacker 5152 IV, 12. 10 | health care [oikea käännös: laki sosiaali- ja terveydenhuollon 5153 III, 10. 2. 1 | Vitrai J (2002): Országos Lakossági Egészségfelmérés, OLEF2000 [ 5154 II, 6. 3. 6 | intestinalis (also called Giardia lamblia), causing both acute and 5155 II, 5. 1. 1 | passage to the intestinal lamina propria or large molecula. 5156 II, 5. 8. 7 | AP, Hoes AW, Salome PL, Lammers JW, Verheij TJ (2005): Prevalence 5157 II, 8. 2. 1 | for the Mentally Retarded (Lammi, Finland). The aetiology 5158 II, 5. 11. 3 | Jolanki R, Kalimo K, Lahti A, Lammintausta K, Lauerma AI, Laukkanen 5159 II, 5. 8. 7 | H, McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P ( 5160 II, 5. 5. 3 | satisfactorily preliminary results: lamotrigine, campath-alemtuzumab, FTY 5161 III, 10. 2. 4 | Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, 5162 II, 5. 2. 7 | Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais 5163 III, 10. 3. 2 | management systems, emergency and land-use planning, and reinforced 5164 II, 5. 9. 4 | disease is still unclear (Landau Paediatr Respir Rev, 2008).~ ~ 5165 II, 5. 6. 6 | Lancet 353:878-882~Combe B, Landewe R, Lukas C, Bolosiu HD, 5166 III, 10. 4. 5 | the environment from the landfilling of waste, by introducing 5167 III, 10. 3. 2 | Annex http ~ ~Grandjean PJ, Landrigan P (2006): Developmental 5168 III, 10. 3. 2 | For example, Grandjean and Landringan (2006) conclude the flowing 5169 III, 10. 4. 3 | flooding, earthquakes or landslide even in societies with well 5170 II, 5. 8. 7 | Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident 5171 IV, 12. 10 | gr/foreas.php?IssueID=8&lang=en). It enumerates 23 member-hospitals ( 5172 II, 9. 1. 1 | countries over the past decade (Langhoff-Ross et al, 2006); these trends, 5173 II, 5. 5. 3 | Psychosen. Eine vergleichende Langzeitstudie. Springer Verlag, Berlin 5174 IV, 11. 4 | risk of cervical cancerLaparoscopic bariatric surgery in severe 5175 II, 5. 4. 8 | References~Armesto SG, Lapetra ML, Wei L, Kelley E and 5176 II, 5. 3. 2 | cases after migration or lapsed attendance to screening 5177 IV, 11. 1. 5 | failures, simple ignorance, lapses in treatment delivery, miscommunication, 5178 II, 5. 5. 3 | Medina-Mora ME, Borges G, Lara C, de Graaf R, Ormel J, 5179 III, 10. 2. 1 | diseases~Childen~Adults~Larinx~Stroke~Brain tumors*~Stroke*~ 5180 II, 9. 3. 3 | Health Metrics 2:5~Kirby D, Laris BA, Rolleri L (2006): Impact 5181 II, 9. 3. 2 | Marchand L, Pierrat V, Larroque B, et al (2007): Neonatal 5182 II, 5. 2. 6 | 362: 1527-1535.~Vasan RS, Larson MG, Leip EP, Evans JC, O' 5183 II, 6. 3. 6 | investigation for Trichinella larvae in meat inspection in the 5184 II, 5. 9. 7 | historical perspective. J Laryngol Otol. Dec;117(12):946-50.~ ~L I ( 5185 III, 10. 2. 1 | M, Kumle M, Rodriguez M, Lasheras C, Janzon L, Jansson J, 5186 II, 5. 3. 9 | Aareleid T, Berrino F, Bielska Lasota M, Carli P, Faivre J, Grosclaude 5187 II, 5. 5. 3 | CF, Bruck W, Rodriguez M, Lassmann H (1996): Distinct patterns 5188 III, 10. 2. 1 | physical activity level. The last-mentioned approach will increase energy 5189 IV, 11. 6. 5 | empowerment and the dilemmas of late-modern medicalisation.” Lancet 5190 III, 10. 5. 3 | noise-induced hearing loss, lateral epicondylitis, contact dermatitis 5191 II, 5. 5. 3 | Modrego Pardo PJ, Pina Latorre MA, López A, Errea JM (1997): 5192 II, 9. 1. 2 | Gatt M, de Walle H, Braz P, Latos-Bielenska A, Gener B, Portillo I, 5193 II, 9. 5. 3 | reported rape as adults~Latviab ( 1998 study )~· 5.2% women 5194 III, 10. 2. 1 | Paalanen L, Prättälä R (2005): Latvijas iedzïvotäju veselïbu ietekmëjošo 5195 II, 5. 11. 3 | Lahti A, Lammintausta K, Lauerma AI, Laukkanen A, luukkaala 5196 III, 10. 1. 3 | Babor TF, Kranzler HR, Lauerman RJ (1987): Social drinking 5197 II, 5. 11. 3 | Lammintausta K, Lauerma AI, Laukkanen A, luukkaala T, Riekki R, 5198 IV, 12. 10 | initiative in Denmark has been launced in January 2008 that focuses 5199 II, 5. 12. 7 | C, Mantion G, Messner M, Launois B, Samuel D, Cherqui D, 5200 II, 5. 7. 7 | 19):2560-72.~Cirillo M, Laurenzi M, Mancini M, Zanchetti 5201 III, 10. 3. 1 | Tirmarche M, Caër S, Quesne B, Laurier D (2007): Lung cancer risk 5202 II, 8. 2. 3 | 42:18-28~ ~Karlsmose B, Lauritzen T, Parving A (1999): Prevalence 5203 III, 10. 2. 1 | Alimentaires. Tec & Doc Lavoisier ed. Paris 2000~Germany~German 5204 IV, 11. 5. 1 | EU:~ ~· one consists of law-approved, institutional centred, 5205 IV, 12. 1 | they will not let a product lawfully marketed in other Member 5206 II, 5. 5.Int(15)| P, Fuhrer R, Hooijer C, Lawlor BA, Kivela S-L, Lobo A, 5207 III, 10. 5. 1 | playing children, bars, lawn-mowing etc.). Using data from the 5208 II, 5. 8. 7 | 485-489.~ ~Goodridge D., Lawson J., Duggleby W.,Marciniuk 5209 II, 5. 5. 3 | physical activity, drug abuse (laxatives, diuretics, enemas or other 5210 II, 9. 3. 1 | incontinence. All four functional layers of the urethra – epithelium, 5211 II, 5. 1. 1 | to a large baby (over 9 lbs/4 kg); or~· has experienced 5212 III, 10. 4. 2 | chromatographyMass Spectrometry (LC-MS), currently monitoring programme 5213 II, 5. 4. 2 | outcomes~ ~HbA1c control ~LDL-C control~Distal outcomes~ 5214 IV, 12. 10 | responsibility. ~The role of LDTFs and RDTFs is to research,~ 5215 II, 5. 11. 3 | piercing posts that do not leach nickel but which contain 5216 III, 10. 4. 5 | exposure to emissions and leachates of existing sites. In the 5217 II, 5. 11. 3 | become discovered from the leaching of silver with formation 5218 III, 10. 4. 2 | Environmental~measures~(lead-free petrol)~ ~ ~IPCS, 1995; 5219 III, 10. 3. 2 | being collected. A ban on leaded petrol has been very successful 5220 II, 5. 7. 5 | now made the UK a world leader in this field. Under QOF, 5221 III, 10. 2. 4 | JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis 5222 I, 2. 10. 3 | The Programme promotes leading-edge technical solutions to improve 5223 III, 10. 5. 1 | the enhancement of canopy leaf area under elevated atmospheric 5224 III, 10. 4. 2 | exposure of workers and leakage into the environment (EU 5225 III, 10. 4. 5 | sites, handling losses, leakages from tanks and pipelines, 5226 IV, 11. 3. 2 | required to dispense the least-cost multi-sourced product. However, 5227 III, 10. 4. 2 | 2005), textiles, carpets, leather furniture, paper, packaging, 5228 II, 5. 2. 7 | Epstein FH, Feldman. JJ, Leaverton PE (1985). Trends in total 5229 III, 10. 3. 2 | zinnorganische Verbindungen in Lebensmitteln und verbraucher nachen Produkten.~ ~ 5230 II, 5. 5. 3 | MS Society’s report “Mehr Lebensqualität, Sympomatische Therapie 5231 II, 5. 5. 3 | herausgegeben von Verband der Lebensversicherungs-Unternehmen eV und Verband der Privaten 5232 II, 5. 5. 3 | Lancet 7;268-277.~Ekestern E, Lebhart G (2004). Mortality from 5233 II, 5. 5. 3 | JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002): Prevalence 5234 III, 10. 2. 1 | Bonenfant S, Goldberg M, Leclerc A (2000): Validity of self-reported 5235 II, 5. 5. 3 | Bourdeaudhuij I, Gonzalez-Gross M, Leclercq C, Kafatos A, Molnar D, 5236 III, 10. 2. 1 | secondary school students (Leclerq et al, 2004) and~· A survey 5237 II, 7. 5 | presentations, supporting lecture notes and other materials 5238 II, 5. 6. 6 | Andersson HI, Ejlertsson G, Leden I, Rosenberg C (1993): Chronic 5239 II, 5. 6. 6 | Spector TD, Hart DJ, and Leedham-Green M (1991): The prevalence 5240 II, 5. 5. 3 | League Against Epilepsy~LICE~Lega Italiana contro lEpilessia~ 5241 III, 10. 2. 1 | and as such should not be legalised. In particular, the public 5242 III, 10. 2. 1 | or dieapproach could be legalizing snuff (Bates et al, 2003).~ 5243 IV, 12. 10 | cutting the frequency of “ legionairesdisease by 50% by 2008~ ~ 5244 IV, 11. 5. 6 | Article 152 of the Treaty, to legislate on quality and safety standards 5245 IV, 11. 1. 5 | clinical guidelines are not legislated, as in Finland, they may 5246 III, 10. 3. 4 | approach and can include: legislating to relocate structures away 5247 II, 9. 5. 3 | muscular pains in the arms or legs (17%), skin diseases, infectious 5248 II, 5. 10. 2 | were cow’s milk, fruits, legumes (especially peanuts and 5249 III, 10. 2. 1 | Bellisle F, Romano MC, Lehingue Y, Frelut ML, Hercberg S ( 5250 III, 10. 4. 2 | Labelling, education~ ~Taylor & Lehrer, 1996;~van Loveren, 2002; ( 5251 IV, 13. 6. 2 | enshrined in their Charter of Leiden. So far, 16 European countries 5252 I, 2. 2 | The report by Rudiger Leidner (2007) entitled “The European 5253 III, 10. 2. 4 | A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch 5254 II, 5. 2. 6 | 1535.~Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell 5255 II, 5. 2. 6 | Karvonen MJ, Kimura N, Lekos D, Monti M, Puddu V, Taylor 5256 II, 5. 5. 3 | T, eaManceau E, Lucas B, Lemesle M, Urbinelli R, Giroud M ( 5257 III, 10. 1. 3 | 3):135-145.~Veenstra MY, Lemmens PHHM, Friesema IHM, Garretsen 5258 II, 5. 9.Acr | Respiratory Health Survey~GA LEN~Global Allergy and Asthma 5259 IV, 12. 1 | Article and, if necessary, lend support to their action.~ 5260 IV, 12. 1 | states" and “if necessary, lending support to their actions” 5261 II, 5. 11. 3 | diseases is an area which lends itself very well to a Europe-wide 5262 IV, 11. 1. 5 | decrease in average patient length-of-stay and 43 less catheter-related 5263 II, 4. 1 | employment in the context of lengthening of life. Drawbacks present 5264 II, 5. 5. 3 | West syndrome 0.5-8%, and Lennox-Gastaut syndrome 2-6%.~Socio-economic 5265 III, 10. 2. 1 | Union: applying an equity lens to tobacco control policies. 5266 II, 8. 2. 2 | of affordable corrective lenses; and cultural disincentives 5267 II, 5. 5. 3 | Disability 1985;38(2):203-10.~Lensky P (1994): Geographic disproportion 5268 II, 5. 5. 3 | J, Gasquet I, Kovess V, Lepine JP, Angermeyer MC, Bernert 5269 II, 5. 11. 3 | T Menné, PJ Frosch, J-P Lepoitterin (eds), 3rd ed. Berlin:Springer, 5270 II, 9. 2. 7 | M, Ollila E, Lahtinen E, Leppo K (eds.) (2006): Health 5271 II, 6. 3. 7 | clinical spectrum, caused by Leptospira bacteria. The death rate 5272 II, 5. 6. 6 | Nakache JP, Gabriel KR, Lequesne M, Amor B (1992): Longitudinal 5273 II, 5. 5. 3 | Byerly MJ, Nakonezny PA, Lescouflair E (2007): Antipsychotic 5274 III, 10. 4. 5 | assessment. Available at: htt ~ ~Lesley Rushton (2003): Health hazards 5275 III, 10. 5. 2 | represents a challenge for the less-developed EU countries.~ ~ ~Table 5276 II, 6. 2 | perfect, and one important lesson to draw is that surveillance 5277 III, 10. 2. 4 | Mastorides S, Dudas ME, Leung DHY, Kuo D, Brennan MF, 5278 II, 5. 5. 3 | Eberhard J, Neovius M, Levander S (2007): Costs of schizophrenia 5279 II, 5. 5. 3 | Education.~Kohn R, Saxena S, Levav I, Saraceno B (2004): The 5280 II, 5. 11. 3 | Mortality rates have also leveled off in Western Europe whereas 5281 III, 10. 2. 1 | increase in activity has levelled off, and the rise in women’ 5282 III, 10. 3. 1 | impacts occurs at a lower lever than what has been known 5283 I, 2. 4 | and overall - will gain leverage from an evidence-based diagnosis 5284 III, 10. 2. 1 | nationella folkhälsoenkäten 2006: levnadsvanor [Results of the national 5285 II, 9. 3. 3 | p37-67.~Cameron KA, Salazar LF, Bernhardt JM, Burgess-Whitman 5286 III, 10. 4. 2 | samples. (Olsen et al, 2005, LGL 2006, Kannan et al, 2004, 5287 II, 5. 5. 3 | Incident cohort~149~58.3~2.6~Lhathoo et al., 2001~ GP: General 5288 II, 5. 5. 3 | Epilepsia 41:1469-1473.~Lhatoo SD, Sander JWAS, Shorvon 5289 III, 10. 2. 1 | General information at: http://lib.bioinfo.pl/pmid:16184880~ 5290 I, 3. 4 | démographique, Ined/John Libbey Eurotext, Paris, 231-251.~ ~ 5291 II, 9. 3. 3 | sexual images from more liberal to more conservative societies ( 5292 II, 9. 3. 1 | troublesome or positive and liberating. Importantly, the knowledge 5293 II, 9. 3. 1 | such as a reduction in libido, erotic fantasies and spontaneous 5294 II, 5. 5. 3 | Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, 5295 III, 10. 4. 2 | data software and spectral libraries rather than by the selective 5296 III, 10. 3. 1 | reduced amounts covered by licenses under the protocol. Both 5297 II, 5. 7. 5 | system of planning; now, licensing and market parties have 5298 II, 5. 11. 3 | photosensitive eczema and lichen simplex. Detailed prevalence 5299 II, 5. 11. 3 | fissuring, vesicles, and lichenification. In addition to primary 5300 II, 5. 5. 3 | Hovatta I, Terwilliger JD, Lichtermann D, Makikyro T, Suvisaari 5301 III, 10. 2. 1 | where multiple illicit and licit substances are used during 5302 II, 5. 10. 7 | Hoffmann-Sommergruber K, Lidholm J, Mustakov T, Oude Elberink 5303 II, 5. 14. 2 | dissemination that should lie within a benchmark methodological 5304 II, 5. 5. 3 | 1715-1722.~Smeets VMJ, van Lierop BAG, Vanhoutvin JPG, et 5305 III, 10. 2. 1 | available at http ~ ~Keil U, Liese AD, Hense HW, et al Classical 5306 III, 10. 2. 1 | Prättälä R (2007): Suaugusių lietuvos ×monių gyvensenos tyrimas, 5307 II, 5. 1. 1 | dominant cause for short life-expectancy, but chronic non-communicable 5308 II, 9. 4. 3 | Mahar, 2003).~ ~ ~Daily life-limiting conditions~ ~Delirium: Delirium, 5309 II, 5. 7. 5 | opportunity to provide potentially life-saving advice and treatment. CKD 5310 II, 9. 3. 3 | information is supplemented by life-skill building (Shepherd J et 5311 I, 2. 6 | taking place during their life-times. This is absolutely essential 5312 II, 8. 2. 1 | different stages of the lifecourse are apparent when countries 5313 II, 9. 5. 3 | domestic violence over their lifetimes (Council of Europe, 2002). 5314 III, 10. 2. 1 | physical activity and other lifeway patterns influencing longevity. 5315 III, 10. 2. 1 | challenges, such as whether to lift the ban on snuff use.~ ~ 5316 II, 5. 8. 7 | Busljetic K, Turato G, Ligabue G, Ciaccia A, Saetta M, 5317 I, 2. 10. 4(10)| sobre los efectos aversos ligados a la hospilitizacion (ENEAS 5318 II, 9. 3. 1 | of the body: the muscles, ligaments, and tendons. Women are 5319 III, 10. 5. 3 | European Union’s action. ‘Lighten the load’ was the theme 5320 I, 2. 7 | reintegrated, using the ideal of lightness as a starting point for 5321 III, 10. 3. 4 | result of the flooding, and lightning killed one man as he tried 5322 II, 5. 9. 7 | and allergic rhinitis in Ligurian children with respiratory 5323 II, 5. 15. 6 | 174(2):189-90.~Dear JW, Lilitkarntakul P, Webb DJ (2006): Are rare diseases 5324 II, 9. 3. 1 | Bergdahl S, Lodding P, Lilja H, Hugosson J (2007): Prostate 5325 III, 10. 3. 4 | France ranging from +4% in Lille to +142% in Paris suggests 5326 II, 9. 1. 2 | Tucker D, Stoll C, Feijoo M, Lillis D, Bianchi F (2005): "Trends 5327 II, 9. 3. 3 | Signorelli C, Pasquarella C, Limina RM, Cozani E, Fanti M, Cielo 5328 II, 5. 7. 7 | 10.~Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin 5329 II, 5. 5. 3 | LG, Gaebel W, Peuskens J, Lindefors N, Richer-Rössler A, Grobbee 5330 II, 5. 8. 7 | Mohangoo AD, van der Linden MW, Schellevis FG, Raat 5331 III, 10. 2. 1 | Osterling A, Nilsson JA, Lindgarde F (2002): Prevention of 5332 II, 5. 6. 6 | Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F (1992): 5333 II, 5. 8. 7 | Lundback B, Lindberg A, Lindstrom M, Ronmark E, Jonsson AC, 5334 III, 10. 3. 1 | Edited by: Berglund B, Lindvall T, Schwela D.~World Health 5335 IV, 11. 1. 6 | includes salary, capitation and line-item or global budgets) or retrospective ( 5336 III, 10. 2. 4 | P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford 5337 III, 10. 2. 1 | Kallestal C, Lagerlof F, Lingstrom P, Mejare I, Norderam G, 5338 III, 10. 3. 1 | assess environment and health linkages and translate knowledge 5339 II, 5. 5. 3 | Schultze-Lutter F, Salokangas RK, Linszen D, Birchwood M, Juckel G, 5340 II, 9. 1. 2 | 642.~Bianchi F, Bianca S, Linzalone N, Madeddu A (2004): Surveillance 5341 III, 10. 2. 1 | and vitamins, especially lipophilic ones.~ ~In conclusion, although 5342 I, 2. 10. 2 | act as a drug vehicle;~- Liposomes: lipid-based nanoparticles, 5343 II, 5. 9. 7 | Cinical Trials. Philadelphia: Lippincot-Raven Press, 1990: 11-23~ ~Sc W ( 5344 II, 5. 5. 3 | 2nd edn. Baltimore, MD: Lippincott Williams & Wilkins; 435– 5345 III, 10. 2. 1 | pills, tablets, capsules, liquids in measured doses.~ ~Directive 5346 III, 10. 2. 1 | experimental Saturday closing of liquor retail stores in Sweden. 5347 IV, 11. 6. 2 | contributions of children (Lisac 2006, cited in Thomson, 5348 II, 5. 11. 3 | 2005;53:4045.~CS Jensen, S Lisby, O Baadsgaard, A Vølund, 5349 II, 5. 2. 7 | Budaj A, Pais P, Varigo J, Lisheng A (2004): Effect of potentially 5350 II, 5. 6. 6 | A, Nguyen M, Thiesce A, Listrat V, Jacob L, Nakache JP, 5351 III, 10. 2. 1 | is what arises from the lit end of a cigarette, mostly 5352 II, 5. 5. 3 | characterized by concrete and literal thinking, obsession with 5353 II, 5. 5. 3 | seltener Krankheiten: eine Literaturstudie. Available at: htt f.~Quik 5354 II, 9. 5. 3 | days killed by her partner~Lithuaniac42.4% of all married/cohabiting 5355 III, 10. 4. 5 | nuisance (smell, noise, litter, effect on property values, 5356 III, 10. 2. 1 | Streets ahead: safe and livable streets for children. London, 5357 I, 2. 7 | possibility of leaving a liveable city to future generations.~ 5358 II, 9. 1. 2 | Survival and Health in Liveborn Infants with Transposition 5359 II, 5. 11. 3 | Sheffield (UK) to 9.1% in Liverpool (UK) (The ESSCA Writing 5360 II, 5. 5. 3 | sclerosis. China: Churchill Livingston Elsevier 671-681.~Minderhoud 5361 II, 5. 5. 3 | edition. New York: Churchill Livingstone, 1998, pp 191-221.~Ebers 5362 II, 9. 3. 2 | in Paediatrics: Churcill Livinstone, 1981.~ ~Magee BD (2004): 5363 II, 5. 6. 6 | van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, 5364 II, 9. 5. 6 | 07)~ ~Cutler D, Deaton A, Lleras-Muney A (2005): The Determinants 5365 III, 10. 5. 3 | adopted measures, for example loans for new machinery, in order 5366 II, 9. 5. 3 | of 16~ a European Women’s Lobby, 2001~b London Metropolitan 5367 IV, 11. 4 | information, public hearings, lobbyists, etc. HTA should be seen 5368 II, 5. 5.Int(15)| Lawlor BA, Kivela S-L, Lobo A, Magnusson H, Mann AH, 5369 II, 5. 10. 2 | crustaceae (shrimps, crab, lobster and crayfish), tree nuts ( 5370 III, 10. 3. 1 | pre-cautionary measures when localising new power lines in densely 5371 IV, 12. 10 | 2007 regarding the list of localities within Romania regions, 5372 II, 5. 6. 6 | social class, and pain localization. Clin J Pain 9:174-182~Arnett 5373 IV, 12. 10 | Funding is being provided for locally-based~cocaine awareness campaigns 5374 IV, 11. 3. 1 | practice. Norway and Sweden locate medical schools in rural areas 5375 II, 5. 7. 7 | Pozzoni P, Vecchio LD, Locatelli F (2007): International 5376 II, 5. 11. 3 | of genetic susceptibility loci have been described.~Examination 5377 II, 5. 5. 3 | Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin 5378 I, 2. 10. 4 | compatibility. End users are not locked into proprietary solutions 5379 II, 5. 14. 3 | ageing adults. In Canada, Locker reported that one third 5380 II, 5. 8. 7 | respiratory health in Europe”. Loddenkemper R, Gibson GJ, Sibille Y 5381 II, 9. 3. 1 | 07~ ~Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J ( 5382 IV, 12. 10 | hostel is available for their lodging.~ ~Work-related health issues~ 5383 III, 10. 5. 2 | Rural Health Conference, Lodi, Italy in 2006.~ ~OECD ( 5384 II, 5. 9. 5 | operating infrastructure (Loeppke, 1999). The strategic framework 5385 II, 5. 12. 2 | regression line to the natural logarithm of the rates using calendar 5386 III, 10. 3. 1 | considerable as shown in the logarithmic scale of Figure 8.1.1.2. 5387 III, 10. 4. 5 | Due to economic and logistical reasons, the management 5388 II, 9. 1. 2 | consent for registration is logistically difficult and requires resources 5389 II, 5. 5. 3 | March 2008).~Berkman, N. D.; Lohr, K. N.; Bulik, C. M. (2007): 5390 IV, 11. 6. 5 | ML, Evans RG, Hertzman C, Lomas J. (1987): "Aging and health 5391 II, 5. 7. 7 | Mancini M, Zanchetti A, Lombardi C, De Santo NG (2006): Low 5392 II, 5. 11. 7 | Forsdyke H et al (1995): London-born black Carriben children 5393 III, 10. 3. 2 | substances, substances used in long-life articles, or delayed effects 5394 III, 10. 3. 1 | surface is largely composed of long-wavelength UV-A.~The atmosphere, stratospheric 5395 II, 9. 5. 1 | between men and women.~ ~Loosening of social norms about women’ 5396 III, 10. 5. 3 | at work include fear of loosing the job, perception of inadequate 5397 II, 5. 8. 7 | 1145.~ ~Van Schayck CP, Loozen JM, Wagena E, Akkermans 5398 II, 5. 5. 3 | Pardo PJ, Pina Latorre MA, López A, Errea JM (1997): Prevalence 5399 II, 5. 5. 3 | J, Hummer M, Dollfus S, Lopez-Ibor J, Hranov LG, Gaebel W, 5400 II, 5. 5. 3 | Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, 5401 II, 9. 5. 1 | responsibilities at home and at work (Lorber, 2005). For what concerns 5402 -, 1 | Scafato, Benedetto Terracini, Lorenzo Tomatis) who met in one 5403 II, 7. 7 | for Europe.~ ~Schopper D, Lormand JD, Waxweiler R (Eds.) ( 5404 IV, 11. 1. 5 | Baptist Medical Center in St. Louis, Missouri which initiated 5405 II, 5. 5. 3 | with Multiple Sclerosis, Louise McVay. This report was actively 5406 II, 9. 3. 3 | personality, communication and love.~ ~The existing evidence 5407 II, 7. 4. 6 | life events (loss of a loved one, loss of a job);~· psychological 5408 II, 5. 11. 3 | cases and 25 000 deaths) and low- and medium-resource countries ( 5409 II, 5. 6. 6 | Epidemiological features of chronic low-back pain. Lancet 354:581-585~ 5410 III, 10. 1. 1 | the exposure to high-fat, low-carbohydrate foods, which have a weak 5411 III, 10. 2. 1 | of a one-litre change in low-consuming countries.~ ~Chronic harm 5412 III, 10. 2. 1 | insulin, a high blood level of low-density lipoprotein cholesterol, 5413 II, 6. 3. 3 | per year in 2004. In the low-incidence countries in central Europe ( 5414 III, 10. 1. 1 | influential compared to low-intensity physical activity (King 5415 I, 2. 5 | issues for older workers. In low-skilled jobs greater attention is 5416 II, 5. 6. 3 | occurrence of characteristic low-trauma fractures, the best documented 5417 II, 5. 7. 7 | Meisinger C, Doring A, Lowel H (2006): Chronic kidney 5418 IV, 11. 3. 2 | incentive to dispense a lower-cost generic equivalent (e.g. 5419 II, 9. 1. 2 | Halliday J, Irgens LM, Lowry RB, McDonnell R, Metneki 5420 II, 5. 9. 7 | Neonatal exposure with LPS and/or allergen prevents 5421 II, 5. 4. 8 | cms_Data/docs/pressdata/en/lsa/89847.pdf] (document online, 5422 IV, 11. 6. 5 | care system going private? LSE Formal Seminar, May 17, 5423 II, 5. 5. 3 | 7Ø ~Ochoa Sangrador and Luaces, 1991 (*)~Spain ~Children > 5424 II, 5. 2. 7 | Manheim LM, Dyer AR, Wang R, Lubitz J et al (2005): Cardiovascular 5425 -, 1 | project.~ ~ Vittorio Silano Luciano Vittozzi~Project Coordinator 5426 II, 8. 2. 1 | 595-502.~Schalock R.L., Luckasson, R.A. and Shogren K.A., 5427 II, 5. 5. 3 | Epilepsia 39:89-92.~Olafsson E, Ludvigsson P, Gudmundsson G, et al ( 5428 III, 10. 2. 1 | Ebbeling CB, Pawlak DB, Ludwig DS (2002): Childhood obesity: 5429 III, 10. 6. 1 | 1985.~ ~Kohb M, Künemund H, Lüdicke J. (2005): Family Structure, 5430 II, 5. 5. 3 | across sectional ~405 ~4.1 ~Luengo et al., 2001 (*)~Sweden~ 5431 II, 5. 6. 6 | 882~Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld 5432 II, 5. 5. 3 | unclear whether PR courses are lumped to RR or PP ones.~ ~Disability~ 5433 II, 5. 5. 3 | level of disability. Further lumping is often needed when precise 5434 III, 10. 3. 2 | C Pettersson, U Wass, M Luna, JC Saenz, J Santamaria ( 5435 IV, 12. 10 | in establishing healthy lunches. As of 2008 general counseling 5436 II, 5. 8. 7 | Jonsson AC, Ronmark E, Lundgren R, Larsson LG, Lundback 5437 III, 10. 2. 1 | Slimani N, Mattisson I, Lundin E, McTaggart A, Allen NE, 5438 II, 5. 10. 5 | Directive 2005/26/EC~- Lupin and products thereof~- Moluscs 5439 III, 10. 2. 1 | L, James M, Jefferson T, Lushey C, Morleo M, Stokes E, Sumnall 5440 II, 5. 6. 6 | Karaharju EO, Porras M, Luthje P, Jakobsson A (1988): Functional 5441 II, 5. 6. 6 | LA, Kaplan SR, Liang MH, Luthra HS, (1988): The American 5442 II, 5. 11. 3 | Lauerma AI, Laukkanen A, luukkaala T, Riekki R, Turjanmaa K, 5443 IV, 12. 8 | Slovenia (2004)~Estonia (2004)~Luxemb0urg (1957)~Finland (1995)~Ireland ( 5444 IV, 11. 6. 3 | higher value-added taxes on luxury goods). Moreover, among 5445 II, 4. 3 | calculation and comparisons. Genus LVII(2): 89-101.~ ~Robine, J.- 5446 II, 5. 9. FB | causing allergies) by Tlymphocytes, a shift that occurs when 5447 III, 10. 3. 1 | GLOBOCAN 2002 database (2002): Lyons, International Agency for 5448 II, 8. 2. 1 | Thompson, J.R., Verdugo, M-A, Wehmeyer, M.L. and Yeager, 5449 II, 9. 3. 2 | Boisbras F, Bouvier-Colle M-H (2006): Epidémiologie de 5450 II, 5. 11. 7 | 1994;131(S44):34.~ ~Johnson M-LT (1978): Skin conditions 5451 III, 10. 2. 5 | Rudic N, Tamminen T, Turunen M-M, Dragonas T, Paradisiotou 5452 II, 8. 2. 1 | In press.~Walsh PN, Kerr M.P, van Schrojenstein Lantman-de 5453 II, 5. 6. 6 | prospective study. J Gerontol 45:M101-M107~Meerding WJ, Bonneux L, 5454 II, 5. 6. 6 | Koopmanschap MA, van der Maas PJ (1998): Demographic and 5455 II, 5. 4. 8 | S200-S204.~Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung 5456 II, 5. 4. 8 | 421-7~Pruna S, Stanciu E, Macarie A, Pruna A, Ionescu-Tirgoviste 5457 II, 5. 4. 8 | Emslie-Smith A, Jung RT, Newton RW, MacDonald TM. (1997), The diabetes 5458 II, 9. 3. 3 | Wellings K, Nanchahak K, Macdowall W, McManus S, Erens B, Mercer 5459 III, 10. 2. 1 | Trends, 2002:25.~ ~Pratt M, Macera CA, Blanton C (1999): Levels 5460 II, 5. 5. 3 | 394.~Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen 5461 IV, 12. 10 | children (“Kinder stark machensee www. ), school-based 5462 II, 5. 6. 6 | Hazes JM, Klareskog L, Machold K, Martin-Mola E, Nielsen 5463 II, 5. 5. 3 | 32: 195-197.~Middelboe T, Mackeprang T, Hansson L, Werdelin G, 5464 II, 5. 10. 7 | 59:1262-8.~ ~Mills ENC, Mackie AR, Burney P, Beyer K, Frewer 5465 II, 5. 8. 2 | bronchitis ( J4 )~J43.0~ ~MacLeod's syndrome~ ~ ~Unilateral:~· 5466 II, 5. 11. 3 | 236.~SH Nguyen, TP Dang, C Macpherson, H Maibach, HI Maibach, 5467 III, 10. 2. 1 | Regional Office for Europe: Macro- and microenvironmental determinants 5468 II, 5. 3. 6 | In this Section mainly macro-analysis results are presented. The 5469 II, 5. 3. 1 | subdivided by geographical macro-area. Moreover, information is 5470 IV, 11. 1. 3 | across countries.~ ~Other macro-level analyses of performance 5471 III, 10. 2. 1 | interventions applied to macro-settings, such as food labelling, 5472 II, 5. 3. 1 | outcomes are related to macro-social indicators and lifestyles ( 5473 IV, 11. 4 | General economic theoryMacroeconomics~· Microeconomics~· Health 5474 II, 9. 1. 2 | Bianca S, Linzalone N, Madeddu A (2004): Surveillance of 5475 II, 8. 2. 1 | Azema, B., Aussilloux, C., Määttä, T., Salvador-Carulla, L., 5476 III, 10. 2. 1 | Blomgren J, Martikainen P, Mäkelä P, Valkonen T, (2004): " 5477 III, 10. 3. 1 | L, Kreuzer M, Lagarde F, Mäkeläinen I, Muirhead C, Oberaigner 5478 II, 5. 5. 3 | Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto 5479 II, 5. 5. 3 | transmission(70):147-151.~Chio A, Magnani C, Schiffer D (1998): Prevalence 5480 II, 5. 7. 1 | cardiovascular diseases are magnified by the epidemics of obesity ( 5481 II, 5. 5. 3 | 46:206-209.~Benedikz J, Magnus S, Guðmundsson J et al ( 5482 II, 5. 5.Int(15)| BA, Kivela S-L, Lobo A, Magnusson H, Mann AH, Meller I, Prince 5483 III, 10. 4. 2 | ΕΛΕΓΧΟΥ ΤΡΟΦΙΜΩΝ EΦET~Greece~Magyar Élelmiszer-biztonsági Hivatal~ 5484 III, 10. 2. 1 | Táplálkozási vizsgálat Magyarországon, 2003-2004 [Dietary survey 5485 II, 5. 2. 6 | 1839.~Robinson JG, Smith B, Maheshwari N, Schrott H (2005). Pleiotropic 5486 III, 10. 1. 1 | et al, 1987; Hart, 2004; Maida, 1984). On the other hand, 5487 IV, 13. 4 | impact of migration will be mainstreamed into the work of the new 5488 IV, 11. 6. 5 | 1149-1162.~ ~Goldfarb NI, Maio V et al. (2003): How Does 5489 III, 10. 2. 1 | Vecchia C, Levi F, McVie JC, Maisonneuve P, Martin-Moreno JM, Newton 5490 III, 10. 4. 2 | dienests~Latvia~Valstybineë maisto ir veterinarijos tarnyba~ 5491 II, 5. 5. 3 | Gaitatzis A, Carroll K, Majeed A, Sander JW (2004): The 5492 III, 10. 3. 2 | that belong to the world majors (CEFIC, 2003) – according 5493 II, 5. 6. 2 | practitioner and policy maker. Bone and Joint Decade, 5494 I, 2. 10. 1 | to optimise the genetic makeup of crops, e.g. improve nutrient/ 5495 II, 5. 5. 3 | Terwilliger JD, Lichtermann D, Makikyro T, Suvisaari J, Peltonen 5496 III, 10. 4. 2 | Rotavirus~GE (children)~Malabsorption~ ~Low~ ~ ~intussusception~ ~ ~ ~ 5497 II, 5. 5. 3 | June 14 2005.~Granieri E, Malagú S, Casetta I, et al (1996): 5498 II, 5. 6. 3 | shown by associations with malalignment, repeated knee bends or 5499 II, 5. 5. 3 | Schürmann A, Michels R, Malchow CP, Dilling H (2002): Comparison 5500 II, 7. 3. 5 | death, psychological harm, maldevelopment, or deprivation“. The definition